ERBB2 and cancer: Trastuzumab and pertuzumab are HER2-directed monoclonal antibodies (mAbs) inducing the recruitment of several immune cells with a subsequent activation of passive immunity, in combination with chemotherapy, these agents downregulate the oncogenic intracellular pathways led by HER2 activation via homo- and hetero-dimerization in the cancer cell membrane [16].